Increasing Prevalence of Inflammatory Disorders
C-reactive protein is one of the common test parameters used to assess, diagnose, and prognose inflammatory diseases in clinical practice. The concomitant occurrence of multiple stimuli of inflammation and influence of factors other than inflammation like smoking, obesity, and physical stress, reduce the specificity of CRP. A regular standardization of measurement techniques and reporting improve the utility of CRP in routine clinical practice. CRP has multiple applications in vitro and in vivo development of potential new compounds for inflammatory diseases. Thus, in the forecast period, the rising prevalence of inflammatory disorders plays a vital role in driving this market.
Other potential factors driving this market are increasing global incidence of endometriosis in women, the rise in funding toward the technological advancement in testing devices, as well as, the rise in the adoption of point of care devices.
Lack of Public Awareness for CRP Tests
The lack of public awareness regarding CRP testing is one of the primary hinderances for the C-reactive testing market. According to a published article of 2016 in Journal of Medicine, Radiology, Pathology & Surgery, in emerging countries such as India, more than 50% of population suffering from diabetes are unaware of the blood tests including CRP tests, for the early diagnosis of diabetes. This also includes the lack of awareness for these tests among clinicians and physicians along with a poor confidence in the usefulness of these tests especially in the emerging markets such as South Asian and African countries.
Another factor impeding this market is the availability of alternative treatments with higher accuracy in hospitals or clinical settings. The healthcare professionals have preference over other blood tests such as erythrocyte sedimentation rate (ESR) tests when compared to C-reactive protein testing, which impedes the growth of this market.
United States to Dominate the Market
The United States is one of the primary markets for critical care diagnostics, and it is expected to dominate the market in the forecast period due to the presence of established multinational players such as LabCorp with multiple manufacturing plants, technological advancements, and well-established healthcare infrastructure. As per the various investigational studies conducted by the National Cancer Institute and the American Association for Cancer Research, showed elevated CRP levels for lungs cancers and colorectal cancer mortality, attracting many companies for investing in the research and development in CRP tests, raising its demand for treatment as well as early diagnosis of the diseases in the United States.
Key Developments in the Market
- January, 2018 - Meso Scale Diagnostic Llc, received 510 (k) clearance from the US FDA for its conventional C-reactive protein assay for in vitro diagnostic use in the United States.
Reasons to Purchase the Report
- Current and future of the global C-reactive protein testing market outlook in the developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- The segment that is expected to dominate the market.
- Regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1.1 Rising Prevalence of Inflammatory Disorders
6.1.2 Increasing Global Incidence of Endometriosis in Women
6.1.3 Rise in Funding Toward the Technological Advancement in Testing Devices
6.1.4 Rise in the Adoption of Point of Care Devices
6.2.1 Lack of Public Awareness
6.2.2 Availability of Alternative Treatments with Higher Accuracy
6.4 Key Challenges
7. Market Segmentation
7.1 By Assay Type
7.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
7.1.2 Chemiluminescence Immunoassay (CLIA)
7.1.3 Immunoturbidimetric Assay
7.2 By Application
7.2.2 Rheumatoid Arthritis
7.2.3 Cardiovascular Diseases
7.2.4 Inflammatory Bowel Disease
7.3 By Geography
7.3.1 North America
126.96.36.199 United States
188.8.131.52 Rest of North America
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
7.3.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
7.3.5 South America
184.108.40.206 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.4 Hoffmann-La Roche Ltd
9.5 Laboratory Corporation of America Holdings
9.6 Merck KGaA
9.7 Quest Diagnostics
9.8 Randox Laboratories Ltd
9.9 Siemens Healthineers
9.10 Thermo Fisher Scientific, Inc.
*List not Exhaustive
10. Future of the Market